Anti-FANCD2 (phospho S1404) antibody [EPR2278(2)] (ab109542)


  • Product nameAnti-FANCD2 (phospho S1404) antibody [EPR2278(2)]
    See all FANCD2 primary antibodies
  • Description
    Rabbit monoclonal [EPR2278(2)] to FANCD2 (phospho S1404)
  • Specificityab109542 only detects FANCD2 phosphorylated at Serine 1404.
  • Tested applicationsSuitable for: ICC/IF, WBmore details
    Unsuitable for: Flow Cyt,ICC,IHC-P or IP
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    A phospho specific peptide corresponding to residues surrounding Serine 1404 of Human FANCD2.

  • Positive control
    • HeLa cell lysate
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.


Associated products


Our Abpromise guarantee covers the use of ab109542 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/200. Use with paraformaldehyde fixed cells, permeabilized with 0.5% Triton X-100.
WB 1/1000 - 1/10000. Predicted molecular weight: 166 kDa.
  • Application notesIs unsuitable for Flow Cyt,ICC,IHC-P or IP.
  • Target

    • FunctionRequired for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching.
    • Tissue specificityHighly expressed in germinal center cells of the spleen, tonsil, and reactive lymph nodes, and in the proliferating basal layer of squamous epithelium of tonsil, esophagus, oropharynx, larynx and cervix. Expressed in cytotrophoblastic cells of the placenta and exocrine cells of the pancreas (at protein level). Highly expressed in testis, where expression is restricted to maturing spermatocytes.
    • Involvement in diseaseDefects in FANCD2 are a cause of Fanconi anemia complementation group D type 2 (FANCD2) [MIM:227646]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
    • Developmental stageHighly expressed in fetal oocytes, and in hematopoietic cells of the fetal liver and bone marrow (at protein level).
    • DomainThe C-terminal 24 residues of isoform 2 are required for its function.
    • Post-translational
      Monoubiquitinated on Lys-561 during S phase and upon genotoxic stress (isoform 1 and isoform 2). Deubiquitinated by USP1 as cells enter G2/M, or once DNA repair is completed. Monoubiquitination requires the FANCA-FANCB-FANCC-FANCE-FANCF-FANCG-FANCM complex, RPA1 and ATR, and is mediated by FANCL/PHF9. Ubiquitination is required for binding to chromatin, interaction with BRCA1, BRCA2 and MTMR15/FAN1, DNA repair, and normal cell cycle progression, but not for phosphorylation on Ser-222 or interaction with MEN1.
      Phosphorylated in response to various genotoxic stresses by ATM and/or ATR. Upon ionizing radiation, phosphorylated by ATM on Ser-222 and Ser-1404. Phosphorylation on Ser-222 is required for S-phase checkpoint activation, but not for ubiquitination, foci formation, or DNA repair. In contrast, phosphorylation by ATR on other sites may be required for ubiquitination and foci formation.
    • Cellular localizationNucleus. Concentrates in nuclear foci during S phase and upon genotoxic stress.
    • Information by UniProt
    • Database links
    • Alternative names
      • DKFZp762A223 antibody
      • FA 4 antibody
      • FA D2 antibody
      • FA4 antibody
      • FAC D2 antibody
      • FACD 2 antibody
      • FACD antibody
      • FACD2 antibody
      • FACD2_HUMAN antibody
      • FAD antibody
      • FAD2 antibody
      • FANC D2 antibody
      • FANCD 2 antibody
      • FANCD antibody
      • FANCD2 antibody
      • Fanconi anemia complementation group D2 antibody
      • Fanconi anemia group D2 protein antibody
      • FLJ23826 antibody
      • OTTHUMP00000158853 antibody
      • OTTHUMP00000207925 antibody
      • Protein FACD2 antibody
      • Type 4 Fanconi pancytopenia antibody
      see all

    Anti-FANCD2 (phospho S1404) antibody [EPR2278(2)] images

    • All lanes : Anti-FANCD2 (phospho S1404) antibody [EPR2278(2)] (ab109542) at 1/1000 dilution

      Lane 1 : HeLa cell lysate, untreated
      Lane 2 : HeLa cell lysate treated with Alkaline Phosphatase.

      Lysates/proteins at 10 µg per lane.

      HRP-labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size : 166 kDa
    • ab109542 (1/200) staining FANCD2 (phospho S1404) in HeLa cells (green). Cells were treated with Bleomycin for 2hrs to induce DNA damage, fixed in paraformaldehyde, permeabilized with 0.5% Triton X-100 and counterstained with DAPI in order to highlight the nucleus (red). For further experimental details please refer to Abreview.

      See Abreview

    References for Anti-FANCD2 (phospho S1404) antibody [EPR2278(2)] (ab109542)

    ab109542 has not yet been referenced specifically in any publications.

    Product Wall

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Immunocytochemistry/ Immunofluorescence
    Sample Human Cell (HeLa)
    Specification HeLa
    Fixative Paraformaldehyde
    Permeabilization Yes - 0.5% Triton-X100 in PBS

    Dr. Kirk Mcmanus

    Verified customer

    Submitted Nov 15 2011